Incidence of platinum-induced ototoxicity in pediatric patients in Quebec

Pediatric Blood and Cancer

Volumn 61, Issue 11, 2014, Pages 2012-2017

  Peleva, Emilia ^a   Emami, Nader ^a   Alzahrani, Mohammad ^a   Bezdjian, Aren ^a   Gurberg, Joshua ^a   Carret, Anne Sophie ^b   Daniel, Sam J ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Late effects of cancer treatment; Ototoxicity; Pediatric oncology; Platinum; Progressive hearing loss

Indexed keywords

CARBOPLATIN; CISPLATIN; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; AUDIOGRAPHY; AUDITORY THRESHOLD; BONE MARROW SUPPRESSION; CANADA; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; INFANT; INFECTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; OUTCOME ASSESSMENT; PERCEPTION DEAFNESS; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION INJURY; RETROSPECTIVE STUDY; SIDE EFFECT; CHEMICALLY INDUCED; STATISTICAL MODEL;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; FEMALE; HEARING LOSS; HUMANS; INFANT; LOGISTIC MODELS; MALE; RETROSPECTIVE STUDIES;

EID: 84912046747     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25123     Document Type: Article

References (36)

1. Rybak LP, Mukherjea D, Jajoo S, et al. Cisplatin ototoxicity and protection: Clinical and experimental studies. Tohoku J Exp Med 2009; 219:177-186.
2. Campbell KCM. Pharmacology and ototoxicity for audiologists. Clifton Park, NY: Delmar; 2007.
3. Rybak LP, Whitworth CA, Mukherjea D, et al. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007; 226:157-167.
4. van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev 2012; 5:CD009219.
5. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer 2009; 52:637-643.
6. Kushner BH, Budnick A, Kramer K, et al. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006; 107:417-422.
7. Dean JB, Hayashi SS, Albert CM, et al. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol 2008; 30:130-134.
8. Massimino M, Spreafico F, Riva D, et al. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol 2010; 100:65-71.
9. Kolinsky DC, Hayashi SS, Karzon R, et al. Late onset hearing loss: A significant complication of cancer survivors treated with cisplatin containing chemotherapy regimens. J Pediatr Hematol Oncol 2010; 32:119-123.
10. Einarsson EJ, Petersen H, Wiebe T, et al. Long term hearing degeneration after platinum-based chemotherapy in childhood. Int J Audiol 2010; 49:765-771.
11. Orgel E, Jain S, Ji L, et al. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. Pediatr Blood Cancer 2012; 58:953-958.
12. American Speech-Language-Hearing Association (ASHA). Audiologic management of individuals receiving cochleotoxic drug therapy [Guidelines]. http://www.asha.org/policy/GL1994-0000 3/. Published 1994. Accessed April 20, 2013.
13. Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 2010; 28:1788-1795.
14. Umansky AM, Jeffe DB, Lieu JEC, et al. Quality of life questionnaire for children with hearing loss. J Am Acad Audiol 2011; 22:644-653.
15. Varni JW, Limbers C, Burwinkle TM. Literature review: Health-related quality of life measurement in pediatric oncology: Hearing the voices of the children. J Pediatr Psychol 2007; 32:1151-1163.
16. Wake M, Hughes E, Collins CZP. Parent-reported health-related quality of life in children with congenital hearing loss: A population study. Ambul Pediatr 2004; 4:411-417.
17. Notteghem P, Soler C, Dellatolas G, et al. Neuropsychological outcome in long-term survivors of a childhood extracranial solid tumor who have undergone autologous bone marrow transplantation. Bone Marrow Transplant 2003; 31:599-606.
18. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer 2004; 40:2445-2451.
19. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77:1355-1362.
20. Dell'Aringa AH, Isaac ML, Arruda GV, et al. Audiological findings in patients treated with radio- and concomitant chemotherapy for head and neck tumors. Radiat Oncol 2009; 4:53.
21. Rybak LP, Ramkumar V. Ototoxicity. Kidney Int 2007; 72:931-935.
22. Yancey A, Harris MS, Egbelakin A, et al. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer 2012; 59:144-148.
23. Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26:649-655.
24. Mukherjea D, Rybak LP. Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics 2011; 12:1039-1050.
25. Ross CJD, Katzov-Eckert H, Dube M-P, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009; 41:1345-1349.
26. Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25:708-714.
27. Neuwelt EA, Brock P. Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol 2010; 28:1630-1632.
28. Knight KR, Kraemer DF, Winter C, et al. Early changes in auditory function as a result of platinum chemotherapy: Use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 2007; 25:1190-1195.
29. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23:8588-8596.
30. Al-Khatib T, Cohen N, Carret AS, et al. Cisplatinum ototoxicity in children, long-term follow up. Int J Pediatr Otorhinolaryngol 2010; 74:913-919.
31. Dreschler WA, van der Hulst RJ, Tange RA, et al. Role of high-frequency audiometry in the early detection of ototoxicity. II. Clinical Aspects. Audiology 1989; 28:211-220.
32. Fausti SA, Henry JA, Schaffer HI, et al. High-frequency monitoring for early detection of cisplatin ototoxicity. Arch Otolaryngol Head Neck Surg 1993; 119:661-666.
33. Arora R, Thakur JS, Azad RK, et al. Cisplatin-based chemotherapy: Add high-frequency audiometry in the regimen. Indian J Cancer 2009; 46:311-317.
34. Singh Chauhan R, Saxena RK, Varshey S. The role of ultrahigh-frequency audiometry in the early detection of systemic drug-induced hearing loss. Ear Nose Throat J 2011; 90:218-222.
35. Abujamra AL, Escosteguy JR, Dall'Igna C, et al. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy. Pediatr Blood Cancer 2012; 60:474-478.
36. Beahan N, Kei J, Driscoll C, et al. High-frequency pure-tone audiometry in children: A test-retest reliability study relative to ototoxic criteria. Ear Hear 2012; 33:104-111.